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Background: Surgery for advanced ovarian cancer (AOC) frequently results in serious 
complications. The present study aimed to determine the importance of various factors and 
complications in cytoreductive surgery for AOC.
Patients and methods: The present study included 90 patients with AOC who underwent 
primary cytoreductive surgery in a single institution from January 2013 to August 2017. 
Demographic and clinicopathologic characteristics, surgical procedures, residual disease, and 
follow-up data were analyzed. Cytoreductive surgery was defined as complete (no residual tumor), 
optimal (residual tumor ,1 cm in diameter), and suboptimal (residual tumor .1 cm in diameter). 
Grade III–IV complications were considered major. Patients were evaluated every 3–6 months.
Results: Surgical outcome was complete in 75 (82%), optimal in 5 (6%), and suboptimal in 11 
(12%) patients. Major complications occurred in 28 (31%) patients. Independent risk factors 
for major complications were $five visceral resections, rectosigmoid resection, glissectomy, 
and pelvic peritonectomy. A score created by weighing the multivariate OR for each risk factor 
correctly predicted major complications in 67% of cases. A score cut-off of .2 discriminated 
between patients with and without complications in 79% of cases (95% CI: 70%–86%, P,0.001). 
Adjuvant chemotherapy was performed as planned in 67 patients (74%), including 50 (75%) 
without major complications and 17 (25%) with major complications.
Conclusion: Risk factors for major complications in cytoreductive surgery for AOC are $five 
visceral resections, rectosigmoid resection, glissectomy, and pelvic peritonectomy. Our model 
predicts morbidity based on major and minor classifications of complications.
Keywords: advanced ovarian cancer, debulking surgery, peritoneal cancer index, residual tumor, 
complications, predictive model, carcinomatosis, cytoreductive surgery, morbidity
Introduction
Advanced ovarian cancer (AOC) surgery aims to achieve maximal cytoreduction in 
order to increase survival and even provide a definitive cure in some cases. Generally, 
this comprises a very aggressive surgery that frequently results in serious postoperative 
complications, including patient mortality or the impossibility of administration of 
subsequent oncological treatments; these complications can directly influence survival.1 
It is difficult to analyze the influence of these postoperative complications due to the 
lack of definition and standardization in the literature, which creates enormous vari-
ability in the results across the various studies published to date; this variability also 
manifests itself in the various predictive models available.2
To evaluate the effect of complications of AOC surgery, several recent studies 
have attempted to systematize the collection of data on postoperative complications 
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and classify their importance in a clear and reproducible 
way. Some of these classification systems are based on the 
intensity of the complication itself (eg, the National Cancer 
Institute’s patient-reported outcomes version of the common 
terminology criteria for adverse events),3 while others are 
based on the complexity of the treatment required (eg, the 
Clavien–Dindo, Accordion, and Memorial Sloan Kettering 
Cancer Center [MSKCC] grading systems).4–6 No classifica-
tion system has yet proven to be definitively more useful and 
better adjusted than the others.
Greater complexity of a classification system can improve 
the precision in stratifying the severity of complications, but 
this comes at the expense of an increase in the dispersion in 
the information referring to the individual influence of the 
various factors involved. Our objective was to analyze whether 
the grouping of complications by severity in the MSKCC 
Secondary Events Grading System5 is sufficiently useful to 
discriminate the importance of various factors and types of post-
operative complications in cytoreductive surgery for AOC and 
to evaluate its consequences on the later course of the disease.
Patients and methods
The present study included patients with stage IIIc and IV 
ovarian, peritoneal, and fallopian tube carcinoma, who under-
went primary cytoreductive surgery at the Multidisciplinary 
Unit of Abdominal Pelvic Oncology Surgery (MUAPOS) of 
the University General Hospital of Castellon (Spain) from 
January 2013 to August 2017. The risk of suboptimal cyto-
reductive surgery (SCS) was evaluated using the radiologic–
laparoscopic criteria for unresectability, and the MUAPOS 
guide to managing AOC was applied in the preoperative 
examination.7 Age and health status were also taken into 
account, and all patients had an Eastern Cooperative Oncol-
ogy Group (ECOG)8 score ,3. All procedures were carried 
out by the same surgical team. Information on the patients’ 
clinical and pathological characteristics, surgical procedures, 
and residual disease at surgery were collected prospectively 
and analyzed retrospectively.
Demographic, clinicopathologic, and follow-up data were 
analyzed. Patients who received neoadjuvant chemotherapy 
were excluded. All patients were staged in accordance with 
the International Federation of Obstetrics and Gynecol-
ogy (FIGO) staging system.9 The Peritoneal Cancer Index 
(PCI) was used to quantitatively assess cancer distribution 
in the peritoneum, based on the calculation of the sizes of 
the lesions in 13 abdominopelvic regions. The sizes of the 
lesions were then converted to scores of 0–3: a lesion size 
score (LSS) of 0 indicates no visible tumor burden in the 
peritoneum, while LSSs of 1, 2, and 3 describe lesions with 
a maximum diameter of 0.5, 5.0, and .5 cm or confluence of 
lesions, respectively. The PCI was calculated by summariz-
ing the LSSs for all regions, giving a maximum PCI10 of 39 
(13×3). The PCI was determined in all patients in the current 
study on preoperative thoracoabdominal computed tomog-
raphy (CT) and/or laparoscopy. To quantify the radiological 
PCI, the largest tumor in the assessed region was chosen and 
assigned a score of 0–3. The sum of the scores for each region 
was then used to calculate the radiological PCI. The PCI was 
calculated pre- and intraoperatively and was categorized into 
two ordinal levels: 1–10 and .10.
Although the principal reference for cytoreductive 
surgery was defined in the consensus statement for colonic 
cancer,10 nowadays some authors are more restrictive with 
respect to the presence of residual tumor after AOC surgery.11 
Complete cytoreductive surgery was defined as no residual 
macroscopic tumor, optimal cytoreductive surgery (OCS) as 
a residual tumor ,1 cm in diameter, and SCS as a residual 
tumor .1 cm in diameter.
For the purpose of the present study, complications of 
grades I–II and III–IV were categorized as minor and major, 
respectively, in accordance with the MSKCC Surgical Sec-
ondary Events Grading System.5 When collecting data regard-
ing complications, procedures that were cancer related (ie, 
diagnostic thoracocentesis for staging) were not considered.
Follow-up of patients started at the time of diagnosis. All 
patients received first-line adjuvant chemotherapy comprising 
six to eight cycles of intravenous carboplatin and paclitaxel. 
After primary adjuvant chemotherapy, the patients were 
evaluated every 3–6 months. The occurrence of relapse and 
the response to first-line chemotherapy were evaluated in 
accordance with response evaluation criteria in solid tumors.12
Written informed consent was provided by the patients, 
and the study was approved by the Ethics and Clinical 
Research Committee of the University General Hospital of 
Castellon. All procedures performed in this study were in 
accordance with the ethical standards of our institution and 
with the 1964 Helsinki declaration.
statistical analysis
The variables were summarized in accordance with their 
nature using the median and IQR, or as frequencies and 
percentages. Univariate analysis was performed with the 
Mann–Whitney test or the Fisher’s exact test. Multivariate 
analysis was performed by logistic binary regression, with 
major complications as the dependent variable and the 
statistically significant factors in the univariate analysis 
as independent variables. A score was calculated for each 
independent risk factor from the multivariate OR. Finally, 
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Table 1 clinicopathological characteristics of all patients
Characteristics Total series (n=90)
age groups (years)  
#60 42 (47%)
.60 48 (53%)
FIgO stage  
III 64 (71%)
IV 26 (29%)
Histology  
serous 71 (79%)
Mucinous 6 (7%)
endometrioid/clear cells 13 (14%)
aacI category  
aacI 0 35 (39%)
aacI 1–3 25 (28%)
aacI 4–8 30 (33%)
computed tomography PcI category  
1–10 47 (52%)
.10 43 (48%)
cea* 1.3 (0.8–2)
ca199* 15.9 (3–38)
ca125* 197 (58–638)
ca153* 34 (16–101)
laparoscopic PcI category  
1–10 22 (24%)
.10 68 (76%)
Operative PcI category  
1–10 40 (44%)
.10 50 (56%)
(Continued)
Table 1 (Continued)
Characteristics Total series (n=90)
number of visceral resections  
0 12 (13%)
1 17 (19%)
2 19 (21%)
3 11 (12%)
4 6 (7%)
5 7 (8%)
6 5 (6%)
7 3 (3%)
8 5 (6%)
9 1 (1%)
11 2 (2%)
13 1 (1%)
14 1 (1%)
Visceral resections  
rectum 29 (32%)
colon 66 (73%)
Bowel 23 (26%)
Urinary bladder 14 (16%)
Ureter 5 (6%)
stomach 6 (7%)
Pancreas 8 (9%)
spleen plus pancreas 26 (29%)
gallbladder 22 (24%)
liver 6 (7%)
glisson 15 (17%)
Diaphragm 12 (13%)
Major vessels 3 (3%)
residual tumor  
ccs 74 (82%)
Ocs 5 (6%)
scs 11 (12%)
Postoperative stay* 17 (11–31)
Note: *Median (IQr).
Abbreviations: aacI, age-adjusted charlson comorbidity Index; ca, carbohydrate 
antigen; ccs, complete cytoreductive surgery (no residual macroscopic tumor); 
cea, carcinoembryonic antigen; FIgO, International Federation of Obstetrics 
and gynecology; Ocs, optimal cytoreductive surgery (residual tumor ,1 cm in 
diameter); PcI, Peritoneal cancer Index; scs, suboptimal cytoreductive surgery 
(residual tumor .1 cm in diameter).
the area under the receiver operating characteristic (ROC) 
curve, sensitivity, specificity, and predictive values of the 
total score for each patient were calculated in accordance 
with the scores of the independent risk factors. Statistical 
analyses were performed using MedCalc 15 for Windows 
(version 15; MedCalc Software, Ostend, Belgium). For all 
univariate tests, a P-value ,0.05 was considered statisti-
cally significant, and a more conservative P-value #0.10 
was considered to indicate the most important risk 
factors in multivariate regression.
Results
During the study period, 90 patients met the inclusion criteria. 
Table 1 summarizes the clinicopathologic characteristics 
of the included patients. The median age was 63 years, 
median Ca 125 was 197 U/mL, number (percentage) of 
patients with FIGO stage III was 64 (73%), median PCI on 
CT was 9, and serous histology was present in 71 patients 
(79%). The cytoreductive surgery outcome was complete 
in 74 patients (82%), optimal in 5 (6%), and suboptimal in 
11 patients (12%).
Table 2 lists the principal factors for major complications. 
There were 247 upper abdominal procedures performed in 
the 90 patients. The most common procedures were pelvic 
peritonectomy, major omentectomy, and right diaphragm 
peritonectomy, which were performed in 61 (67%), 69 
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(76%), and 44 (48%) patients, respectively. Pelvic perito-
nectomy included common procedures such as hysterectomy 
and bilateral salpingo-oophorectomy. Pelvic and aortic 
lymphadenectomy was performed in 51 patients (56%). 
Visceral resections were performed in 78 patients (86%), 
with 25 patients (27%) undergoing five or more resections. 
The median estimated blood loss was 1,600 mL, with a 
median surgical time of 370 minutes.
Major complications occurred in 28 patients (31%). Of 
the 28 patients with major complications, 17 cases (61%) 
were managed by placing percutaneous or transvaginal drains 
for abdominal collections. Digestive leakages were found 
in ten patients (11%), and colorectal leakages occurred in 
three patients (3%).
The 30-day postoperative mortality rate was 2%. Logistic 
regression analysis identified four independent risk factors 
for major complications: five or more visceral resections, 
combined rectal and sigmoid resection, glissectomy, and 
pelvic peritonectomy. A predictive score for major compli-
cations was built through weighing the multivariate OR for 
each independent risk factor (Table 3).
The scores of each patient correctly predicted the occur-
rence of major complications in 67% of cases. The calibra-
tion and discrimination power of the model was validated 
using the same data from the series (narrow validation). For 
an optimal score cut-off of .2, the discrimination between 
patients with and without complications was 79% (area 
under the ROC curve, 95% CI: 70%–86%, P,0.001). The 
sensitivity was 68%, and the specificity was 82%. For a gen-
eral prevalence of major complications of 31%, the positive 
predictive value was 63% and the negative predictive value 
was 85%. Calibration of the model was assessed by compar-
ing the predicted probabilities estimated from the predictive 
model with the actual observed proportion of patients with 
the outcome of interest (Figure 1).
The postoperative adjuvant chemotherapy plan for the 
90 patients was to treat them with platinum and taxane 
chemotherapy for at least six cycles within 8 weeks postop-
eratively. Of the 90 patients, 67 (74%) were able to start the 
six cycles of chemotherapy on time. Twenty-three patients 
(26%) did not complete the prescribed postoperative che-
motherapy, which was due to death in 4 patients (including 
Table 2 Main prognostic factors for major complications
 Total series 
(N=90)
No/minor complications 
(n=62)
Major complications 
(n=28)
P-valuea
computed tomography PcI category    0.042
1–10 47 (52%) 37 (60%) 10 (36%)  
.10 43 (48%) 25 (40%) 18 (64%)  
Operative PcI category    0.005
1–10 40 (44%) 34 (55%) 6 (21%)  
.10 50 (56%) 28 (45%) 22 (79%)  
rectal resection 29 (32%) 15 (24%) 14 (50%) 0.027
sigmoid resection 37 (41%) 20 (32%) 17 (61%) 0.020
combined rectosigmoid resection 22 (24%) 10 (16%) 12 (43%) 0.009
spleen–distal pancreas resection 26 (29%) 12 (19%) 14 (50%) 0.005
glissectomy 15 (17%) 6 (10%) 9 (32%) 0.013
number of visceral resections    0.002
,5 65 (72%) 51 (82%) 14 (50%)  
$5 25 (28%) 11 (18%) 14 (50%)  
Peritonectomy    0.017
none 14 (16%) 9 (15%) 5 (18%)  
Partial 48 (53%) 39 (63%) 9 (32%)  
complete 28 (31%) 14 (23%) 14 (50%)  
Pelvic peritonectomy 60 (67%) 38 (61%) 22 (79%) 0.15
Note: aFisher’s exact test.
Abbreviation: PcI, Peritoneal cancer Index.
Table 3 Multivariate analysis: logistic regression for the presence 
of major complications
Risk factors for major complications OR P-value Score
Five or more visceral resections 3.6 0.07 2
rectosigmoid resection 3.1 0.02 1.5
glissonian peritonectomy 4.3 0.09 2
Pelvic peritonectomy 2.2 0.10 1
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the two postoperative mortalities) and the administration of 
chemotherapy outside of the planned time in 19 patients. 
Also, 81% (50/62) of patients without major postoperative 
complications received adjuvant treatment, compared with 
60% (17/28) with major complications.
Patients with a score .2 showed a trend toward worse 
overall survival (HR =1.6, P=0.10; Figure 2).
Discussion
Morbidity and mortality are generally considered the prin-
cipal endpoints in AOC surgery. Our results suggest that 
the most important risk factors for major complications in 
AOC surgery were .5 visceral resections, rectosigmoid 
resection, and Glissonian and pelvic peritonectomy. The 
proposed model predicted these complications in nearly 70% 
of patients in our series.
In 2013, upper abdominal surgical (UAS) techniques 
were incorporated into the cytoreductive approach for 
advanced ovarian, fallopian, and peritoneal carcinomas.13 
This led to a significant improvement in optimal cytore-
ductive rates, and improved overall and progression-free 
survival.7 Previous research reported that UAS techniques 
were required to achieve OCS in a large proportion of patients 
with AOC.14 Requirement of UAS techniques is not currently 
considered a contraindication to primary debulking surgery 
(PDS) in centers with an aggressive surgical protocol and 
higher rates of OCS.14,15
While previous studies have evaluated the advantages of 
incorporating these surgical techniques in terms of achiev-
ing OCS,14 the risk of complications associated with these 
procedures was not specifically evaluated. In the present 
study, we included patients who were optimally cytoreduced 
with standard surgical procedures and with UAS techniques, 
which could have led to a lowered complication rate. How-
ever, considering that UAS techniques had to be applied in 
nearly two-thirds of the patients in the present series,16 both 
standard techniques and UAS had to be considered together 
to accurately quantify morbidity and mortality associated 
with PDS in AOC.
Digestive anastomosis after intestinal resection is related 
to the occurrence of postoperative complications in patients 
undergoing extensive cytoreduction surgery. The anasto-
motic leakage rate after resection of a segment of the colon, 
especially in rectosigmoid resection, is reportedly 3%–15%.17 
In our series, dehiscence of the anastomosis occurred in ten 
patients (11%), of which three (3%) had undergone colorectal 
anastomosis. Performing protective ostomy after colorectal 
anastomosis is a controversial issue.18 Our group restricts 
the use of protective ostomy only to those patients requiring 
ultralow rectal resections or those in whom more than two 
intestinal resections were performed.
In the present study, we chose to focus on intraoperative 
factors, as surgical complexity is determined by the pro-
cedures performed during surgery. The next step could be 
the prediction of these surgical maneuvers using preopera-
tive CT images, as described in other predictive models.2 
Some institutions are now using laparoscopic assessments 
Figure 1 calibration for an optimal score cut-off of .2.
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Figure 2 Overall survival in accordance with the score for major complications.
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to determine resectability in patients with AOC.11 We have 
previously described a combination of preoperative CT 
and diagnostic laparoscopy to determine the tumor burden 
in AOC by calculating the PCI.16 The same previous study 
reported that patients with a PCI .20 required three or more 
visceral resections.16 Using this preoperative combination of 
CT and laparoscopy to identify intraoperative risk factors for 
complications and mortality may be more useful for both 
clinicians and patients.
In the present study, the rate of major complications 
was 31% and the mortality rate was 2%. This postoperative 
mortality rate after extensive cytoreductive surgery is in the 
same range as other individual and population-based studies 
that report an average mortality in the perioperative period 
of 2.5%–3.7%.19
Although half of the complications in the present study 
were managed with less aggressive techniques, these compli-
cations were directly related to the completeness of or adher-
ence to adjuvant treatments. As reported in previous studies,20 
we believe that major complications have a prognostic impact, 
indicating that a substantial delay in and/or omission of adju-
vant therapy play a prognostic role. We defined the patients 
suitable for surgery as those with an ECOG score ,2, but 
other authors have used a wider concept of frailty to assess 
the actual fitness of patients for surgery in order to prevent 
delaying the chemotherapy;21 this could be the reason why 
there were 18 patients in the present study in whom chemo-
therapy was performed outside of the planned timeframe.
The strengths of the present study include the homoge-
neous cohort of patients, and the single-institution uniform 
approach to care and inclusion of patients with AOC, making 
it relevant to those at the greatest risk of surgical morbidity 
and mortality.
The limitations of the present study include the retrospec-
tive design and the optimistic biased performance of our 
model performed via internal validation. However, we feel 
that including those common surgical factors performed in 
most AOC cytoreductive surgeries makes this model relevant 
in most settings. Nevertheless, external validation of this 
model in other settings is mandatory.
In conclusion, given the substantial survival benefit 
obtained from maximal cytoreduction, the management guide-
lines of AOC should allow a balanced approach to short-term 
morbidity and long-term benefit. Clinicians must always 
take into account that a greater degree of surgical aggression 
induces a greater number of serious complications, and these 
major complications may worsen the prognosis. We present a 
simple predictive model of morbidity based on major and minor 
classifications of complications, which will be useful in patient 
counseling and will aid clinicians and patients in making deci-
sions regarding PDS. Some patients will be better managed 
using an alternative approach (neoadjuvant chemotherapy), 
but PDS is reasonable and well tolerated by the majority of 
patients. Further strategies to reduce surgical complications, 
plus referral of patients to experienced surgical teams should 
enable further reductions in morbidity and mortality.
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